Olympus (FRA:OLY1) Cyclically Adjusted Revenue per Share: €3.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OLY1 Olympus Corp FRA:OLY1
77 GF Score
Price €9.61
GF Value €14.24
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Olympus Cyclically Adjusted Revenue per Share?

Olympus FRA:OLY1 +0.13% 77 Cyclically Adjusted Revenue per Share is €3.98 as of Mar. 2026. GuruFocus rates FRA:OLY1 with a GF Score™ of 77/100 and a GF Value™ of €14.24 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Olympus's adjusted revenue per share for the three months ended in Mar. 2026 was €1.445. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Olympus's average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Olympus was 5.90% per year. The lowest was -4.20% per year. And the median was -2.15% per year.

As of today (2026-07-29), Olympus's current stock price is €9.606. Olympus's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €3.98. Olympus's Cyclically Adjusted PS Ratio of today is 2.41.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Olympus was 5.19. The lowest was 1.12. And the median was 2.88.


Olympus  (FRA:OLY1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Olympus's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.606/3.98
=2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Olympus was 5.19. The lowest was 1.12. And the median was 2.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Olympus Cyclically Adjusted Revenue per Share Related Terms


Olympus Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Olympus's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Olympus Cyclically Adjusted Revenue per Share Chart

Olympus Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.35 4.32 3.84 4.33 3.98

Olympus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.33 4.19 4.04 3.90 3.98

FRA:OLY1 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Olympus's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olympus Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Olympus's Cyclically Adjusted PS Ratio falls into.


FRA:OLY1
77GF Score
Olympus Corp FRA:OLY1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Olympus Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Olympus's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.445/112.7000*112.7000
=1.445

Current CPI (Mar. 2026) = 112.7000.

Olympus Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.040 98.100 1.195
201609 1.151 98.000 1.324
201612 1.092 98.400 1.251
201703 1.262 98.100 1.450
201706 1.007 98.500 1.152
201709 1.093 98.800 1.247
201712 1.107 99.400 1.255
201803 1.200 99.200 1.363
201806 1.028 99.200 1.168
201809 1.126 99.900 1.270
201812 1.142 99.700 1.291
201903 1.240 99.700 1.402
201906 1.090 99.800 1.231
201909 1.264 100.100 1.423
201912 1.237 100.500 1.387
202003 1.267 100.300 1.424
202006 0.877 99.900 0.989
202009 1.124 99.900 1.268
202012 1.213 99.300 1.377
202103 1.303 99.900 1.470
202106 1.122 99.500 1.271
202109 1.159 100.100 1.305
202112 1.131 100.100 1.273
202203 1.218 101.100 1.358
202206 1.066 101.800 1.180
202209 1.243 103.100 1.359
202212 1.237 104.100 1.339
202303 1.338 104.400 1.444
202306 1.080 105.200 1.157
202309 1.162 106.200 1.233
202312 1.272 106.800 1.342
202403 1.308 107.200 1.375
202406 1.184 108.200 1.233
202409 1.305 108.900 1.351
202412 1.377 110.700 1.402
202503 1.473 111.100 1.494
202506 1.097 111.700 1.107
202509 1.276 112.000 1.284
202512 1.296 113.000 1.293
202603 1.445 112.700 1.445

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.98 mean?
Olympus (FRA:OLY1) has a Cyclically Adjusted Revenue per Share of €3.98 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Olympus and its competitors.
Is Olympus' Cyclically Adjusted Revenue per Share too high?
Olympus' current Cyclically Adjusted Revenue per Share is €3.98. Overall, Olympus has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Olympus' Cyclically Adjusted Revenue per Share of €3.98 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Olympus and its competitors. Olympus's current Cyclically Adjusted Revenue per Share is €3.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (FRA:OLY1) is currently considered Significantly Undervalued. The stock's GF Value™ is €14.24, compared to a current price of €9.61 — trading 32.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.98. Olympus' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Olympus (FRA:OLY1), the current Cyclically Adjusted Revenue per Share is €3.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Olympus (FRA:OLY1) Overvalued in 2026?

Based on GuruFocus' analysis, Olympus stock appears to be undervalued. The current stock price of €9.61 is trading 32.5% below its estimated GF Value™ of €14.24. GuruFocus considers Olympus to be Significantly Undervalued.

Key valuation signals for FRA:OLY1:

  • Cyclically Adjusted Revenue per Share: €3.98
  • GF Value™: €14.24 vs. price of €9.61 (32.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the FRA:OLY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Olympus Business Description

Address 2951 Ishikawacho, Hachioji, JPN, 192-8507
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
77GF Score

Get the complete analysis for FRA:OLY1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.61
Price
€14.24
GF Value